QL1706 With Olaparib for Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency (HRD)

NCT07113964 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

79

Enrollment

OTHER

Sponsor class

Conditions

Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency

Interventions

DRUG: QL1706 + olaparib

Sponsor

The First Affiliated Hospital with Nanjing Medical University